Equity Details
Price & Market Data
Price: $0.671
Daily Change: -$0.007 / 1.04%
Daily Range: $0.656 - $0.69
Market Cap: $166,235,456
Daily Volume: 341,204
Performance Metrics
1 Week: -9.59%
1 Month: 6.25%
3 Months: 19.30%
6 Months: 83.78%
1 Year: 65.98%
YTD: 97.10%
About Vaxart, Inc. (VXRT)
Get insights into Vaxart, Inc. (VXRT)'s financial health. With a price of 0.671, the stock shows a -$0.007 / 1.04% daily change. Its market cap is 166,235,456. Detailed performance for 1-month (6.25%) and 52-week (65.98%) periods are crucial.
Company Details
Employees: 74
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; COVID-19 Vaccine, which is in Phase 2b clinical trial for the treatment of SARS-CoV-1, SARS-CoV-2, and Middle East respiratory syndrome coronavirus; Seasonal Influenza vaccine, which is in Phase 2 clinical trial, to treat H1N1 Influenza; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.